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WE agree with Gary Gibson that the "test of a good hypothesis is 
not whether it is right or wrong, but that it stimulates productive 
and revealing experiments." In our review, we presented two 
distinct hypotheses. First, we summarized evidence suggesting 
both pre- and postsynaptic disruption of  excitatory amino acid 
(EAA) pathways in Alzheimer's disease and we have hypothesized 
that these abnormalities may account for some of the clinical 
manifestations of this disease. Second, we have proposed that 
EAA, by virtue of their excitotoxic properties, might play a role in 
the pathogenesis of Alzheimer's disease. Our review was inten- 
tionally provocative and the commentators have raised a number 
of interesting points, some of which we will address below. 
Little disagreement exists that EAA-utilizing neurons are 
affected in Alzheimer's disease. Determination of the extent of 
EAA system damage in Alzheimer's disease is limited by the lack 
of an adequate, stable marker for EAA neurons in postmortem 
brain. As Dr. McGeer indicates in her commentary, phosphate- 
activated glutaminase is a potential marker for EAA neurons, but 
its specificity is uncertain. If glutaminase proves to be a reliable 
marker for EAA neurons, the much greater loss of glutaminase in 
Alzheimer's disease than of choline acetyltransferase will be of 
immense interest. These results could indicate an early, severe loss 
of EAA neurons in Alzheimer's disease. 
We agree with Cotman et al, that NMDA receptor loss is not 
widespread in mild to moderate Alzheimer's disease and that 
receptor loss in advanced Alzheimer's disease is likely related, in 
part, to cell loss. We disagree, however, with their interpretation 
of the current literature regarding NMDA/PCP receptor losses in 
Alzheimer's disease and with the conclusion " i t  now appears that 
NMDA receptor number is relatively maintained in cases of 
moderate cell loss in AD so that the cellular density of NMDA 
receptors may actually increase . . . .  " This conclusion is per- 
plexing since they report an average decline of  40% in TCP 
binding in CA1 of Alzheimer's hippocampus (8) which was 
statistically significant (p<0.013), despite their implication to the 
contrary in the commentary. A critical examination of the litera- 
ture would indicate that no published study has investigated the 
relationship of NMDA receptor number to neuronal cell counts or 
the integrity of neuronal processes in Alzheimer's disease. Only 
reports of NMDA receptor binding relative to binding to other 
receptors have appeared (3,4). These studies, indeed, indicate that 
NMDA/PCP receptors are more reduced than other receptors in 
CA1 in Alzheimer's hippocampus. Considerably more detailed 
postmortem information must be obtained before drawing such 
strong, albeit intriguing, conclusions based on limited data. In 
addition, ascribing hippocampal cell death in Alzheimer's disease 
to agonal hypoxia appears unwarranted until some additional 
supportive data are obtained. We disagree also with Cotman et 
al.'s interpretation of our previous studies of  [3H]glutamate 
binding in calcium and chloride (4). We have studied in detail the 
properties of the calcium/chloride-dependent [3H]glutamate bind- 
ing site in autoradiographic binding studies (1,2). (Cotman and 
colleagues have studied ion-dependent binding in homogenates 
and this homogenate binding has very different properties than the 
autoradiographic binding sites we have described.) The autora- 
diographic site is located postsynaptically on neurons, not glia. is 
unlikely to be a transport site and probably represents binding to 
both the ion channel-linked quisqualate receptor and the quis- 
qualate-linked metabotropic receptor (1,2). We have also con- 
firmed the large loss of NMDA receptors (>80%) in hippocampus 
of severe AD cases by examining NMDA displaceable binding 
directly in the original series of cases [(3); J. B. Penney et al.. 
submitted]. 
Dr. McGeer suggests that "measurements of the integrity of 
glycine and PCP modulation" of the NMDA receptor complex 
"might  be more revealing than simple measurements of NMDA 
binding density." This is apparently true. Autoradiographic stud- 
ies from our lab, as well as from Carl Cotman's lab. have shown 
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substantial and significant losses (40-55%; p<0.02) of PCP sites 
in CA1 of Alzheimer's disease hippocampus (6,8). In contrast, 
homogenate studies of binding to the PCP site have shown no 
changes in PCP receptors in the hippocampus of Alzheimer's 
disease patients (9,11). What is the difference between autora- 
diographic and homogenate binding assays? Aside from the 
enhanced anatomical resolution obtainable with autoradiography, 
the residual ambient glycine levels may be critical. It is extremely 
difficult to remove all of the endogenous glycine from slide- 
mounted tissue sections, whereas it is much easier to remove 
glycine in homogenate membrane preparations. In our autoradio- 
graphic assay, adding exogenous glycine to the assay results in a 
variable, modest (10-40%) increase in [3H]MK-801 binding to the 
PCP site. When the tissue sections are washed more rigorously, 
glycine induces a larger, more consistent increase in [3H]MK-801 
binding (S. Y. Sakurai et al . ,  unpublished results). As David 
Bowen and colleagues report in their commentary, glycine can 
induce a 300% increase in [3H]MK-801 binding in well-washed 
membrane preparations from human cortical material. In Alzhei- 
mer's disease cortex, Bowen and colleagues observed a marked 
reduction in this glycine-induced increase in [3H]MK-801 binding. 
Thus, glycine modulation of the NMDA receptor complex appears 
to be altered in Alzheimer's disease; PCP sites themselves may not 
be as severely affected. This finding may help to explain the 
discrepancy between PCP receptor binding in Alzheimer's disease 
in autoradiographic versus homogenate preparations. In autora- 
diographic assays, where there is residual endogenous glycine, 
glycine enhancement of PCP receptor binding is substantial and, 
therefore, autoradiographic PCP receptor binding is, in part, a 
measure of glycine modulation. However, in well-washed ho- 
mogenate preparations in which glycine has been effectively 
removed, there will be little if any glycine enhancement and 
therefore less apparent change in PCP receptor binding in Alzhei- 
mer's disease. 
As we pointed out in our review, EAA mechanisms may be a 
secondary cause of neuronal damage in Alzheimer's disease 
because neurons which have been compromised by some other 
pathological process become more susceptible to NMDA neuro- 
toxicity. Drs. Lee and Sapolsky et al. both emphasize that multiple 
factors rather than a unitary process are likely to be responsible for 
the selective neuronal vulnerability observed in Alzheimer's dis- 
ease. As Dr. Henneberry's lab has shown, when neuronal ATP 
levels are compromised by hypoglycemia, hypoxia, inhibition of 
oxidative phosphorylation or inhibition of Na+/K + ATPase activ- 
ity, glutamate is an extremely potent neurotoxin, with an LDso of 
about 20 txM. (Incidentally, Dr. Henneberry's findings address 
Dr. Gibson's concern that the level of glutamate observed after 
ischemic insults is insufficient to cause neuronal damage.) These 
findings are even more intriguing in the light of Dr. Gibson's 
finding that the activity of 2-oxoglutarate dehydrogenase is re- 
duced by more than 75% in Alzheimer's brains. Because the 
enzyme is central to oxidative metabolism as well as to the 
metabolism of glutamate and aspartate, this dramatic reduction 
might be expected to decrease neuronal ATP levels and increase 
glutamate levels. A possible "feed-forward" cycle can be con- 
ceived in which reduced levels of 2-oxoglutarate dehydrogenase 
result in increased glutamate and aspartate levels and decreased 
oxidative metabolism with resultant decreased ATP levels. This 
cycle would render the neurons more susceptible to excitotoxic 
damage and lead to increased intracellular calcium levels which 
would, in turn, irreversibly inactivate 2-oxoglutarate dehydroge- 
nase. As the neurons die and are lysed by excitotoxic mechanisms, 
more EAA would be released and cause further excitotoxic 
damage. 
Dr. May notes that glutamate interferes with cystine transport 
and results in glutathione depletion and subsequent sensitization to 
free radical damage. This interesting observation suggests yet 
another mechanism by which EAA may contribute to the patho- 
genesis of the pathology in Alzheimer's disease. It will be of 
interest to study the distribution of free radical-scavenging en- 
zymes and enzymes involved in oxidative metabolism in normal 
brains as well as Alzheimer's disease brains. Such studies may add 
to our understanding of the selective vulnerability of restricted cell 
populations as well as the advanced age of onset seen in Alzhei- 
mer's disease. 
Other EAA-related factors may also help to explain the 
distribution of the pathology of Alzheimer's disease. As we 
mentioned in our review, and as Edith McGeer emphasizes, there 
may be subtypes of NMDA receptors. Furthermore, glycine and 
PCP modulation of NMDA receptors may not be uniform through- 
out the brain. Thus, regional variations in the degree of glycine- 
PCP-NMDA coupling could also help to explain the type of 
selective damage which occurs in Alzheimer's disease. As Dennis 
Choi and his colleagues have demonstrated, non-NMDA receptors 
may also mediate excitotoxic neuronal damage. Of course, it is 
difficult to study such mechanisms in Alzheimer's disease. The 
development of assays to measure quisqualate receptors linked to 
ion channels and those linked to inositol triphosphate metabolism 
(1,2) in postmortem brain should further our understanding of the 
role of these EAA receptors in Alzheimer's disease. In addition, 
we have recently described an unique glutamate binding site which 
is distinct from NMDA, quisqualate or kainate receptors (5). This 
site is located postsynaptically on neurons, has a submicromolar 
affinity for glutamate, an unique regional distribution and an 
interesting pattern of development. The function of this site is 
unknown and whether it can mediate neurotoxic events remains to 
be determined. Preliminary experiments indicate that this site is 
depleted in Alzheimer's disease hippocampal formation. Whether 
glutamate can still exert excitotoxic effects in the presence of 
saturating concentrations of both N M D A  and quisqualate/kainate 
antagonists needs to be determined. If so, such effects may be 
mediated by the recognition site we have identified. 
Drs. Gibson and McGeer have correctly pointed out that under 
certain circumstances, other neurotransmitters, such as dopamine 
and acetylcholine, may also be neurotoxic. While these neuro- 
transmitters may have direct neurotoxic effects, it is also possible 
that their toxicity results from an interaction with EAA mecha- 
nisms. As we discussed in our review, and as emphasized by Dr. 
Henneberry, anything which depolarizes neurons, including ace- 
tylcholine or dopamine, renders those neurons more vulnerable to 
excitotoxicity. Perhaps the toxicity produced by these other 
neurotransmitters could be ameliorated by EAA antagonists. 
Relevant to this, Schwarcz and Kohler (10) demonstrated cholin- 
ergic modulation of kainate toxicity. Brian Meldrum and col- 
leagues have shown that NMDA antagonists protect against 
pilocarpine-induced limbic seizures (and, presumably, the associ- 
ated neuronal damage) (7). 
Several issues were raised with respect to beta-N-methylamino- 
L-alanine (BMAA). First, we agree with Dr. McGeer that BMAA 
is unlikely to activate EAA receptors directly. However, as Weiss 
and Choi (12) have demonstrated, BMAA in the presence of 
bicarbonate is excitotoxic and produces excitatory electrophysio- 
logical responses. Second, we agree with Dr. Choi that BMAA 
likely activates NMDA as well as non-NMDA receptors. Third, 
Dr. McGeer has raised the possibility that the structure of BMAA 
suggests that it might act at the glycine recognition site. We have 
examined this issue directly (J. W. McDonald et al. ,  submitted) 
and can find no evidence for such an interaction. 
Therapeutic modulation of excitatory amino acid neurotrans- 
mission in Alzheimer's disease might have two goals. First, since 
there is apparently disruption of EAA neurotransmission in this 
disease, replacement therapy may be considered. Second, since 
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excitotoxic mechanisms may play a role in the pathogenesis of 
Alzheimer's disease, antagonism of excitotoxicity might be of 
benefit. In large part, these strategies appear to be mutually 
exclusive. Dr. Bowen and his colleagues believe that the glycine 
modulatory site may be an attractive target for therapeutic inter- 
vention. This may be true, but which will be better--a glycine 
agonist to potentially enhance cognition, or a glycine antagonist to 
retard disease progression? A partial glycine agonist may actually 
provide the best solution. Because of the convincing evidence that 
non-NMDA receptors can mediate excitotoxic events, Dr. Choi 
has suggested that non-NMDA receptor antagonists might have 
therapeutic benefit. However, non-NMDA EAA receptors proba- 
bly mediate a large portion of the fast synaptic neurotransmission 
in the central nervous system, so antagonism of these receptors 
may have profound deleterious results. As we suggested, it may be 
possible to exploit EAA agonists as "cognition enhancing" drugs, 
by combining their use with agents that block specifically the 
postreceptor mechanisms responsible for toxicity. As Dr. Choi 
points out, voltage-gated calcium channels may be such a post- 
receptor target. Finally, as Dr. May proposes, antioxidant agents 
may reduce EAA toxicity without interfering with normal neuro- 
transmission. 
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